Backgrounds/Aims: We compared the efficacy and safety of a hepatectomy, combined with intraoperative radiofrequency ablation to those of wider extent hepatectomy, alone, in patients with multiple hepatocellular carcinomas (HCCs). Methods: Between January 2004 and December 2013, 78 patients with multiple HCCs underwent surgery. 25 patients were treated by hepatectomy, combined with intraoperative radiofrequency ablation (RFA) (group A), and 53 underwent hepatectomy only (group B). We retrospectively analyzed medical records to compare the clinical features of these two groups. Results: Patients in group A had more limited resections (less than 2 segments) than those in group B (p＜0.001). Patients in group A also tended to have fewer red blood cell transfusions than those in group B (p=0.060). Liver function-and surgery-related complications occurred only in group B. There were no in-hospital mortalities in both groups. The overall survival and disease-free survival outcomes were not significantly different between groups A and B (p=0.177 and p=0.305, respectively). Conclusions: Hepatectomy combined with intraoperative RFA could be a safe and effective treatment option for patients with multiple HCCs, comparable to extended hepatectomy alone. 
INTRODUCTION
Hepatic resection is generally considered the gold standard for the treatment of patients with hepatocellular carcinoma (HCC). [1] [2] [3] [4] However, previous studies report a low rate of resectability for HCC, in the range of 20% to 40%. 4, 5 Surgical treatment is not considered appropriate for most patients, because of poor remnant hepatic function, distant metastasis, major vascular invasion, unsuitable tumor location, and multinodular tumor distribution. [1] [2] [3] [4] [5] Moreover, palliative treatments have produced disappointing survival benefits for patients with unresectable HCCs; 6-8 studies show that surgical resection produces a better prognosis than palliative treatments. 9, 10 Radiofrequency ablation (RFA) has been recently established as an effective treatment method, and is regarded as one of the curative treatment options for select HCC patients. [11] [12] [13] According to a recent study, RFA is a safe and effective method for managing HCC patients with cirrhosis, especially for patients with a tumor size ≤2 cm, and poor hepatic reservoir function. 12 Intraoperative RFA has some theoretical advantages over percutaneous RFA, including better visualization of the tumor on intraoperative ultrasonography. 13 Intraoperative RFA also enables more accurate placement of the electrodes, and reduces the risk of bleeding. 13 Hepatic failure, due to intraoperative RFA, is less likely to occur in this circumstance than after a hepatectomy of wider extent.
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Multiple tumorectomies, or an extended hepatectomy, are indicated for patients with multiple HCC. However, they involve a higher risk of hepatic failure, perioperative massive transfusion, and postoperative complications.
Therefore, hepatectomy combined with intraoperative RFA (H-RFA) has the advantage of reducing operative risk after the hepatectomy. Additionally, H-RFA may broaden the applicability of surgery for multiple HCC treatments.
The purpose of this study was to evaluate the efficacy and safety of H-RFA for multiple HCCs. 
MATERIALS AND METHODS

Between
RESULTS
The clinicopathological data for the 78 patients enrolled in this study are summarized in Table 1 Moreover, there were no statistically significant differences in the overall or disease-free survival rates between groups A and B (Figs. 1, 2) . The overall survival rate, at 5 years, was 72.1% in group A and 52.0% in group B (p=0.177). The disease-free survival rate at 5 years was 29.7% in group A and 23.9% in group B (p=0.305).
Furthermore, the marginal recurrence following the intraoperative RFA was 16.7%.
DISCUSSION
The reasons for the lack of curative treatments for patients with multiple HCCs include insufficient hepatic reservoirs after resection, impaired hepatic function with cirrhosis, and an improper surgical approach for bilobar tumor distribution. However, the survival benefits after pal- liative treatment for these patients have been disappointing, as documented in previous studies. 6, 7 Cammá et al. 6 reported that, in randomized studies, the survival benefit of hepatic arterial chemoembolization in these patients was relatively small. Llovet et al 7 .
showed that chemoembolization improved the overall survival for only 20% of responders. A study of the palliative treatment in 268 HCC patients, who did not satisfy the Milan criteria, yielded poor survival outcomes with only 24% being alive at 5 years. 15 Additionally, sorafenib was reported to improve the survival period by only 3 months in patients with advanced HCCs. 8 However, Ng et al. 9 reported favorable survival outcomes after hepatic resection for large or multiple HCCs, with 5-year overall survival rates of 39%. They suggested that the long-term survival outcomes in patients without poor prognostic variables were comparable to those with early HCC. Yin et al. 10 suggested that hepatic resection may be the treatment of choice for resectable multiple
HCCs that do not meet the Milan criteria. Furthermore, they reported a 3-year overall survival rate of 51.5%.
These studies indicate that hepatic resection could be a curative treatment option for patients with resectable HCC.
Recently, RFA has been recommended for patients with early HCC as a curative treatment option. [1] [2] [3] [4] Kim et al. 16 reported excellent long-term survival outcomes for patients with early HCC after percutaneous RFA; the 10-year survival rate was 38.2%. However, they also reported that tumor recurrence after RFA was frequent, with 10-year intrahepatic and extrahepatic recurrence rates of 88.5% and 38.2%, respectively. Intraoperative RFA has some theoret- Choi et al. 18 described the long-term survival outcomes of patients with multifocal HCC, who underwent H-RFA.
They reported that the 5-year overall survival rate, after H-RFA, was 55% and that the intrahepatic marginal recurrence rate was 3%. They also reported no hospital mortalities, and an RFA-related complication rate of 2%. A resected tumor size ≥5 cm was the only independent prognostic factor for survival.
In this present study, there were no significant differences in the overall and disease-free survival outcomes, between patients who underwent H-RFA and those who underwent hepatectomy alone. Furthermore, the marginal recurrence rate was 16.7%, which is consistent with the previous study reported by Kim et al. 16 Thus, we conclude that H-RFA is an effective treatment modality for patients with multiple HCC. Expanding the possibilities for the curative resection of HCC will lead to better prognoses for patients with multiple HCC. Additionally, patients with H-RFA experienced a lower complication rate than those with hepatectomy alone, although this difference was not statistically significant. Liver function-related or surgery-related complications occurred only in patients who underwent hepatectomy alone.
In conclusion, the results of our study suggest that H-RFA is a safe and effective treatment option for patients with multiple HCCs, comparable to extended hepatectomy alone.
